News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Revenue from operations up 26% to Rs. 768 crores
Subscribe To Our Newsletter & Stay Updated
